Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares Global Tech ETF (IXN) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares Global Tech ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares Global Tech ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while iShares Global Tech ETF trades at $142.59. Which is the better fit depends on your goals.

AMLXIXN
Market Cap
$2.64B
Sector
HealthSector/Thematic
52-Week High
$24.19$149.74
52-Week Low
$7.82$94.42
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

iShares Global Tech ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares Global Tech ETF

IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.

Read more on IXN